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Anxiety disorders are characterized by persistent, excessive fear. Therapeutic interventions that reverse
deﬁcits in fear extinction represent a tractable approach to treating these disorders. We previously re-
ported that 129S1/SvImJ (S1) mice show no extinction learning following normal fear conditioning. We
now demonstrate that weak fear conditioning does permit fear reduction during massed extinction
training in S1 mice, but reveals speciﬁc deﬁciency in extinction memory consolidation/retrieval. Rescue
of this impaired extinction consolidation/retrieval was achieved with D-cycloserine (N-methly-D-aspar-
tate partial agonist) or MS-275 (histone deacetylase (HDAC) inhibitor), applied after extinction training.
We next examined the ability of different drugs and non-pharmacological manipulations to rescue the
extreme fear extinction deﬁcit in S1 following normal fear conditioning with the ultimate aim to produce
low fear levels in extinction retrieval tests. Results showed that deep brain stimulation (DBS) by applying
high frequency stimulation to the nucleus accumbens (ventral striatum) during extinction training,
indeed signiﬁcantly reduced fear during extinction retrieval compared to sham stimulation controls.
Rescue of both impaired extinction acquisition and deﬁcient extinction consolidation/retrieval was
achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC
inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA
(AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice. Collectively, these data
identify potential beneﬁcial effects of DBS and various drug treatments, including those with HDAC
inhibiting or mGlu7 agonism properties, as adjuncts to overcome treatment resistance in exposure-based
therapies.
This article is part of a Special Issue entitled ‘Cognitive Enhancers’.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Anxiety disorders, such as post-traumatic stress disorder, social
phobia, speciﬁc phobias, panic and obsessive-compulsive disorders,
are among the most common mental disorders in humans (Olesen
et al., 2012). These disorders are associated with problems to
extinguish learned fear responses and also to consolidate extinction
memories (Myers and Davis, 2007; Milad et al., 2009). To date, the
most effective strategies in the treatment of anxiety disorders; fax: þ43 (0)512 507 58899.
le).
-NC-ND license.include use of pharmacological and cognitive strategies (Nutt,
2005). However, signiﬁcant drawbacks to current therapy exist
including lack of treatment response and also a lack of long-term
beneﬁcial effect of combining available drugs with exposure-
based therapy (Barlow et al., 2000; Davidson et al., 2004; Foa
et al., 2005; Yehuda and LeDoux, 2007; Norberg et al., 2008).
Clinical interventions which rescue deﬁcits in fear extinction
acquisition and consolidation would constitute important treat-
ment options in these disorders. Along these lines, pharmacological
and genetic silencing studies, predominantly in normally behaving
rodents and using massed extinction training paradigms, have
identiﬁed a number of neurobiological mechanisms that govern
acquisition of fear extinction learning and extinction consolidation.
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(NMDA) receptor 2B (Sotres-Bayon et al., 2007), a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) (Zushida
et al., 2007; Yamada et al., 2009) and metabotropic glutamate 7
(mGlu7) (Fendt et al., 2008) receptor activities in addition to
GABAergic signalling [for example, see (Harris and Westbrook,
1998; Chhatwal et al., 2005; Akirav et al., 2006; Lin et al., 2009;
Dalton et al., 2012)], amongst others. Following acquisition of
extinction, there is a consolidation phase which lasts up to several
hours which serves to stabilize plastic events into long-term
memory (McGaugh, 2000). Activation of NMDA receptors (Davis,
2011), brain-derived neurotrophic factor (BDNF) signalling
(Chhatwal et al., 2006; Soliman et al., 2010) and inhibition of
histone deacetylases (HDAC) (Guan et al., 2009; McQuown et al.,
2011), amongst others, are important for consolidation of extinc-
tion [for detailed reviews, see (Myers and Davis, 2007; Quirk and
Mueller, 2008; Herry et al., 2010; Pape and Pare, 2010; Steckler
and Risbrough, 2011; Orsini andMaren, 2012; Tronson et al., 2012)].
The present study used isogenic 129S1/SvImJ (S1) mice which
display deﬁcient extinction acquisition, poor recovery of fear-
induced suppression of heart-rate variability, enlarged dendritic
arbours in basolateral amygdala neurons and functional abnor-
malities in cortico-amygdala circuitry mediating fear extinction
(Hefner et al., 2008; Camp et al., 2009, 2012;Whittle et al., 2010). In
the current study we reduced the intensity of fear conditioning and
observed that “weak” fear conditioning allowed for extinction
acquisition in S1 mice but revealed deﬁcient extinction retrieval.
Recent ﬁndings show that impaired extinction acquisition and
dysfunctional cortico-amygdala circuitry can be rescued by a novel
zinc restricted diet (Whittle et al., 2010), which interestingly did
not affect either fear learning or fear expression. Also, recent
ﬁndings reveal that the S1 fear extinction phenotype can be rescued
by ﬂuoxetine (a serotonin-selective reuptake inhibitor) (Camp
et al., 2012) which is of clinical relevance as serotonin-selective
reuptake inhibitors are ﬁrst-line treatment for anxiety disorders
(Nutt, 2005). Considering the well-known disadvantages of long-
term SSRI treatments, we screened for novel treatments which
rescue both deﬁcient extinction acquisition and extinction
consolidation/retrieval in S1 mice.
Evidence suggests that deep brain stimulation (DBS) of the
nucleus accumbens (AcbC) can enhance extinction-like behaviour
in intractable obsessive-compulsive disorder patients, which is
characterised by avoidance behaviours that fail to extinguish
(Lipsman et al., 2007; Burdick et al., 2009; Goodman et al., 2010;
Greenberg et al., 2010; Grant et al., 2011). Furthermore, a small
clinical study involving patients suffering from treatment-resistant
depression has shown that DBS of the AcbC can enhance various
measures of cognition independent of mood status (Bewernick
et al., 2012). However, there are also reports of no effect of AcbC-
DBS in mood disorder patients (Grubert et al., 2011). Very
recently, DBS of the AcbC during extinction training reduced fear
expression and strengthened extinction memory in normally
behaving rats (Rodriguez-Romaguera et al., 2012) potentially
showing the utility of DBS of the AcbC as a novel fear reducing
adjunct during exposure-based therapy. Here, we went beyond
using normally behaving rodents and assessed whether DBS of the
AcbC during extinction training can rescue deﬁcient extinction
acquisition and extinction consolidation/retrieval in S1 mice.
Pharmacological compounds which enhance glutamatergic
signalling, including DCS (NMDA receptor partial agonist), PEPA
(AMPA receptor potentiator) or AMN082 (mGlu7 receptor agonist),
can facilitate fear extinction in normally extinguishing animal
models and in clinical studies (Myers et al., 2011). We have previ-
ously shown that prior extinction training administration of DCS is
ineffective in rescuing deﬁcient extinction learning in S1 mice(Hefner et al., 2008). However, it remains unknown whether DCS
can rescue deﬁcient extinction consolidation/retrieval once at least
some extinction learning is induced, which we revealed in “weak”
fear conditioned S1 mice. Furthermore, it is not known whether
PEPA or AMN082 can reduce fear in an animal model of impaired
extinction.
Drugs inhibiting HDAC proteins to prevent the removal of acetyl
groups on histone tails is a promising approach in central nervous
system disorders associated with disturbed learning and memory
(Kazantsev and Thompson, 2008). Interestingly, inhibiting HDACs
has been shown to enhance fear learning (Guan et al., 2009) and
rescue deﬁcits in fear learning in mouse models of anxiety or
neurodegeneration (Li et al., 2006; Dash et al., 2009; Kilgore et al.,
2010). Facilitation of fear extinction by HDAC inhibition has been
reported in normally extinguishing mice (Bredy et al., 2007; Lattal
et al., 2007; Bredy and Barad, 2008; Guan et al., 2009; Monsey et al.,
2011). However, it is not known whether inhibiting HDACs can
improve extinction learning in animal models of impaired extinc-
tion. Thus, we tested whether valproic acid (VPA), a dual HDAC
inhibitor and enhancer of GABAergic signalling or MS-275, a more
speciﬁc HDAC inhibitor (Khan et al., 2008; Bantscheff et al., 2011),
can rescue deﬁcient extinction in S1 mice.
2. Materials and methods
2.1. Subjects
Subjects were male 3e5 month old 129S1/SvImJ (S1) mice. For experiments
performed at the University of Innsbruck, mice (obtained from Charles River,
Germany) were housed (4e5 per cage) in a temperature- (22  2 C) and humidity-
(50e60%) controlled vivarium under a 12 h light/dark cycle (lights on at 7:00 A.M.).
For experiments conducted at the National Institutes of Health, mice (obtained from
The Jackson Laboratory, USA) were housed (2 per cage) in a temperature (221 C)-
and humidity (45  15%)-controlled vivarium under a 12 h light/dark cycle (lights
on, 6:00 A.M.). All experimental procedures were approved by the Austrian Animal
Experimentation Ethics Board and by the National Institute on Alcohol Abuse and
Alcoholism Animal Care and Use and Austrian Ethical Committees on Animal Care
and Use (Bundesministerium für Wissenschaft und Verkehr, Kommission für Tier-
versuchsangelegenheiten) and followed the National Institutes of Health guidelines
outlined in Using Animals in Intramural Research and the local animal care and use
committees.
2.2. General procedures for fear conditioning and extinction
For experiments performed at the University of Innsbruck, mice were condi-
tioned in a 25  25  35 cm chamber with transparent walls and a metal rod ﬂoor,
cleanedwith water and illuminated to 300 lux (‘context A’). After a 120 s acclimation
period, there were 3 pairings of a 120 s, 80 dB white noise conditioned stimulus
(CS) and a 2 s scrambled foot shock unconditioned stimulus (US) (0.6 mA unless
stated otherwise), with a 120 s inter-pairing interval. There was a 120 s no-stimulus
consolidation period after the ﬁnal pairing before mice were returned to the home
cage. Extinction training was performed the next day in a 25 25 35 cm cagewith
a solid grey ﬂoor and black walls, cleaned with a 100% ethanol and illuminated to 10
lux (‘context B’). After a 120 s acclimation period, there were CS-alone trials (16
unless stated otherwise), with a 5-sec inter-CS interval. Stimulus presentation was
controlled by a TSE operant system (TSE, Bad Homburg, Germany). Extinction
retrieval was conducted the following day by repeating the extinction training
procedure but with 2 CS trials. Freezing was measured as an index of fear
(Blanchard and Blanchard, 1969), manually scored based on DVD recordings of the
duration of the CS, deﬁned as no visible movement except that required for respi-
ration, and converted to a percentage [(duration of freezing within the CS/total time
of the CS)  100] by a trained observer blind to the animals’ group.
For experiments performed at NIAAA, mice were conditioned in
a 27 27 11 cm chamber with a metal-rod ﬂoor, cleaned with a 79.5% water/19.5%
ethanol/1% vanilla-extract solution (‘context A’). After a 180 s acclimation period,
there were 3 pairings (60e120 s inter-pairing interval) of the conditioned stimulus
(CS; 30 s 80 dB, 3 kHz tone) and the unconditioned stimulus (US; 2 s, 0.6 mA
scrambled foot shock), in which the US was presented during the last 2 s of the CS.
The session ended 120 s after the ﬁnal CSeUS pairing. Stimulus presentation was
controlled by the Med Associates VideoFreeze system (Med Associates, Burlington,
VT, USA). 24 h after conditioning, extinction training was conducted in a novel
context (‘context B’) (cylinders with black/white-chequered walls and a solid Plex-
iglas opaque ﬂoor cleaned with a 1% acetic acid/99% water solution) housed in
a different room from conditioning. After a 180 s acclimation period, there were 16
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B 48 h after extinction training. After a 180 s acclimation period, there were 3 CS
presentations (5-sec inter-CS interval). Freezing (no visible movement except
respiration) was scored every 5 s by an observer blind to condition/treatment and
converted to a percentage [(freezing observations/total observations)  100].2.3. Extinction in S1 mice after weak versus normal fear conditioning
Procedures and apparatuses for normal fear conditioning were as described
above and involved 3 pairings of the CS with a 0.6 mA US. The weak fear condi-
tioning procedure was the same with the exception that the US was 0.3 mA. Mice
were randomly assigned to either weak or normal fear conditioning and tested for
extinction training and retrieval as above (Fig. 1A).2.4. Effects of deep brain stimulation of the nucleus accumbens
Mice were anaesthetized with a mixture of ketamine/xylazine (80/5 mg/kg)
injected intraperitoneally (i.p.). Using a stereotaxic frame, electrodes (MS303-3-B-SPC,
bipolar, twisted, 8 mm, Plastics ONE, USA) were implanted unilaterally, targeting the
core of the nucleus accumbens. The coordinates were þ1.10 mm anterior to
Bregma, þ1.45 mm lateral from midline, 4.65 mm ventral according to the atlas of
(Franklin and Paxinos, 2008). Electrodes were ﬁxed to the skull with 2 stainless steel
screws anddental cement (HavardCement, Richter&HoffmannHarvardDentalGmbH,
Germany). After surgery animals were individually caged and received buprenorphin
(0.1 mg/kg injected intraperitoneally) every 8 h for 3 days to minimise pain.
After 4e5 days of recovery, micewere conditioned via 5 pairings of the CS with
a 0.7 mA US. Extinction training began with 2 CS-alone trials without DBS to
measure fear expression in the absence of any inﬂuence of DBS before presenting
16 CS-alone extinction trials. DBS (130 Hz, 100 mA, 60 ms pulse width) was applied
via an A310 Accupulser and A365 Stimulus Isolator (World Precision Instruments,
Sarasota, USA) throughout the CS period during each 16 CS extinction trials
(Fig. 2A). Sham controls were connected to the stimulator but received no current. At
the completion of testing, the localization of electrodes was conﬁrmed from
inspection of cresyl violet stained coronal sections (Fig. 2C), and mice with mis-
placed electrodes were excluded.Fig. 2. DBS of the AcbC during extinction training reduces fear in S1 mice. A) Sche-
matic of experimental design. B) Sham and DBS groups did not differ in freezing during
“stronger” fear conditioning (Cond.). DBS did not alter fear expression as no differences
were observed in the DBS group during the ﬁrst CS-block in which the stimulator was
off and the ﬁrst CS-block (CS-block 2) when the stimulator was on. Freezing did not
differ between Sham and DBS groups during the remainder of extinction training2.5. Effects of VPA administration
Mice were conditioned via 3 pairings of the CS with a 0.6 mA US. 100 mg/kg
VPA (Sigma, St. Louis, USA) or saline vehicle was injected i.p. in a volume of 10 ml/kg
body weight 2 h prior to extinction training (Fig. 3A). The dose, route and timing of
administration was based on previous studies showing extinction facilitating effects
of VPA in mice (Bredy et al., 2007; Bredy and Barad, 2008) and that 2 h is required
before maximal histone acetylation is observed (Tremolizzo et al., 2005).Fig. 1. Comparison of “normal” and “weak” fear conditioning paradigms during fear
conditioning (Cond.), extinction training (Ext.) and extinction retrieval (Ext. Ret.). A) Sche-
matic of experimental design. B) No differences in freezing were observed during fear
conditioning or fear expression between “normal” and “weak” fear conditioned groups.
During extinction training, “weak” fear conditioned mice displayed reduced freezing
compared to “normal” fear conditioned mice. No differences in freezing behaviour were
observed between “normal” and “weak” fear conditioned mice during extinction retrieval.
0¼baseline/pre-tonefreezing levels. *p<0.05 “normal”vs. “weak” fearconditionedgroups.
(Ext.). Lower freezing was observed in DBS mice during an extinction retrieval session
(Ext. Ret.). C) Schematic diagram showing electrode placement in the AcbC. Diagram
adapted from Franklin and Paxinos (2008). Sham stimulated mice are shown as ﬁlled
circles and DBS stimulated mice are shown as white ﬁlled circles. Level indicated is
mm from Bregma. 0 ¼ baseline/pre-tone freezing levels. *p < 0.001 Sham vs. DBS.2.6. Effects of AMN082 administration
Mice were conditioned via 3 pairings of the CS with a 0.6 mA US. 6 mg/kg
AMN082 (Tocris Bioscience, Bristol, United Kingdom) or saline þ 0.5% methylcel-
lulose vehicle was administered per oral (p.o.) via gavage in a volume of 10 ml/kg
body weight 2 h prior to extinction training (Fig. 4A). The dose, route and timing of
administration was based on previous studies showing extinction facilitating effects
of AMN082 in mice (Fendt et al., 2008).
2.7. Effects of PEPA administration
Mice were conditioned via 3 pairings of the CS with a 0.6 mA US. 10 or 30 mg/
kg PEPA (Sigma, St. Louis, USA) or saline þ 0.45% NaCl þ 33% (2-hydroxypropyl)-b-
cyclodextrin vehicle was injected i.p. in a volume of 10 ml/kg body weight 15 min
prior to extinction training (Fig. 5A). The doses, route and timing of administration
was based on previous studies showing extinction facilitating effects of PEPA inmice
(Zushida et al., 2007; Yamada et al., 2009).
2.8. Effects of MS-275 administration
Mice were conditioned via 3 pairings of the CS with a 0.6 mAUS. 5 or 10mg/kg
MS-275 (Sigma, St. Louis, USA) or saline þ 25% DMSO vehicle was injected i.p. in
a volume of 10 ml/kg body weight 2 h prior to extinction training (Fig. 6A). The
doses, route and timing of administration was based on a previous study showing
that maximal increases in histone acetylation occurs 2 h following s.c. injection of
MS-275 (Simonini et al., 2006).
Fig. 3. VPA, administered prior to extinction training, rescues impaired extinction
acquisition and deﬁcient extinction consolidation/expression in S1 mice. A) Schematic
of experimental design. B) During extinction training (Ext.), freezing was lower in VPA
treated S1 mice than VEH S1 mice on CS presentation blocks 2e8. Lower freezing was
observed in VPA treated S1 mice during extinction retrieval (Ext. Ret.). No differences
in freezing was observed between VEH and VPA groups during “normal” fear condi-
tioning (Cond.). 0 ¼ baseline/pre-tone freezing levels. *p < 0.05 VEH vs. VPA.
Fig. 5. PEPA, administered prior to extinction training, does not rescue deﬁcient
extinction acquisition or deﬁcit extinction consolidation/retrieval in S1 mice. A)
Schematic of experimental design. B) Freezing responses did not differ between VEH or
10 or 30 mg/kg MS-275 groups during “normal” fear conditioning (Cond.), extinction
training (Ext.) or an extinction retrieval session (Ext. Ret.). 0 ¼ baseline/pre-tone
freezing levels.
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Micewere conditioned via 3 pairings of the CS with a 0.3 mAUS. 10mg/kg MS-
275 (Eubio, Vienna, Austria), 15 mg/kg DCS (Sigma, St. Louis, USA) or saline þ 25%
DMSO vehicle was injected i.p. in a volume of 10 ml/kg body weight immediately
(<2 min) after extinction training (Fig. 7A). The doses, route and timing of admin-
istration of MS-275 was based on our earlier experiment and the doses, route and
timing of administration of DCS was based on previous studies showing extinction
facilitating effects in rats and humans (Walker and Davis, 2002; Ressler et al., 2004;
Richardson et al., 2004).
2.10. Statistical analysis
All data were examined for equal variances using Levene’s test before per-
forming parametric tests. Data were analyzed using analysis of variance (ANOVA),
with repeated measures for trial/trial-block, or by Student’s t-test. Signiﬁcant
ANOVA results were followed by Fisher’s LSD post hoc tests.Fig. 4. AMN082, administered prior to extinction training, rescues impaired extinction
learning and deﬁcient extinction consolidation/retrieval in S1 mice. A) Schematic of
experimental design. B) During extinction training (Ext.), freezing was lower in
AMN082 treated S1 mice than VEH S1 mice on CS presentation blocks 3e8. Lower
freezing was observed in AMN082 treated S1 mice during extinction retrieval (Ext.
Ret.). No differences in freezing were observed between VEH and AMN082 groups
during “normal” fear conditioning (Cond.). 0 ¼ baseline/pre-tone freezing levels.
*p < 0.05 VEH vs. AMN082.3. Results
3.1. Weak fear conditioning in S1 mice permits fear reduction
during extinction training, but not retrieval
We have previously found that the level of fear expression in S1
mice can be modulated by the intensity (shock amplitude, shock-
tone trial number) of fear conditioning (Camp et al., 2009). There-
fore, we asked whether extinction in S1 was graded by the intensity
of conditioning. There was a signiﬁcant and similar increase in
freezing across 3 conditioning trials inmice given 0.3mAand0.6mA
shocks [ANOVA effect of trial: F(2, 20) ¼ 80. 15, p < 0.001; effect of
group: p> 0.05, interaction: p> 0.05, n¼ 6/group] (Fig. 1B). During
extinction training, there was a signiﬁcant group  trialeblock
interaction for freezing (F(7, 70) ¼ 8.71, p < 0.001). Post hoc tests
revealed that the weak shock group displayed lower freezing than
the 0.6 mA group on blocks 3e8, but not blocks 1 or 2 (Fig. 1B).
However, during extinction retrieval, freezing was not differentFig. 6. MS-275, administered prior to extinction training (arrow), does not rescue
deﬁcient extinction acquisition or deﬁcit extinction consolidation/retrieval in S1 mice.
A) Schematic of experimental design. B) Freezing responses did not differ between VEH
or 5 or 10 mg/kg MS-275 groups during “normal” fear conditioning (Cond.), extinction
training (Ext.) or an extinction retrieval session (Ext. Ret.). 0 ¼ baseline/pre-tone
freezing levels.
Fig. 7. Post extinction administration of DCS or MS-275 rescues impaired extinction
consolidation/retrieval in S1 mice. A) Schematic of experimental design. B) Lower
freezing was observed during a retrieval test (Ext. Ret.) when DCS or MS-275 was
administered immediately following successful extinction (arrow). Groups did not
differ in freezing responses either during “weak” fear conditioning (Cond.) or during
extinction training (Ext.). 0 ¼ baseline/pre-tone freezing levels. *p < 0.05 VEH vs. DCS;
#p < 0.01 VEH vs. MS-275.
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while thisweak conditioning procedure did not reduce fear learning
or expression compared to normal conditioning, it did allow for
signiﬁcant fear reduction during the extinction learning trial in S1
mice. However, extinction memory was not successfully consoli-
dated/retrieved on the next day.
3.2. Deep brain stimulation of the nucleus accumbens rescues
impaired extinction retrieval
We ﬁrst examined the effects of DBS of the AcbC, applied during
extinction training, on impaired extinction in S1 mice. During
conditioning, freezing increased across trials and did not differ
between groups [ANOVA effect of trial: F(4, 64) ¼ 109.80, p < 0.001,
effect of group: p > 0.05, interaction: p > 0.05, n ¼ 9/group]
(Fig. 2B). DBS during extinction training did not affect freezing, as
compared to sham-stimulated controls, as both groups showed no
change in freezing across trial-blocks [ANOVA effect of group:
p > 0.05, effect of trial-block: p > 0.05, group  trial-block inter-
action: p > 0.05] (Fig. 2B). During extinction retrieval, freezing was
signiﬁcantly lower in DBS than sham controls during extinction
retrieval (t16¼ 2.96, p< 0.01) (Fig. 2B). These results show that DBS
of the nucleus accumbens rescued extinction retrieval, but not
extinction acquisition, in S1 mice.
3.3. VPA rescues impaired extinction learning and retrieval
We next examined the effects of 3 diverse pharmacological
compounds, applied acutely prior to extinction training, on
impaired S1 extinction. Our ﬁrst experiment tested the effects of
VPA. During conditioning, freezing increased across trials and did
not differ between groups [ANOVA effect of trial: F(2, 32) ¼ 347.05,
p < 0.001, effect of group: p > 0.05, interaction: p > 0.05, n ¼ 8e9/
group] (Fig. 3B). There was a signiﬁcant group  trial block inter-
action for freezing during training (F(7, 98)¼ 3.24, p< 0.01). Post hoc
tests showed freezing was signiﬁcantly lower in the VPA group
relative to vehicle, on trial-blocks 2e8 (Fig. 3B). During extinction
retrieval, freezing was again signiﬁcantly lower in the VPA than thevehicle group (t15 ¼ 4.75, p < 0.001) (Fig. 3B). These data show that
VPA rescues impaired extinction learning and retrieval in S1 mice.
3.4. AMN082 rescues impaired extinction learning and retrieval
Our next experiment examined the effects of pre-extinction-
administered AMN082. During conditioning, freezing increased
across trials and did not differ between groups [ANOVA effect of
trial: F(2, 28)¼ 90.25, p< 0.001, effect of group: p> 0.05, interaction:
p > 0.05, n ¼ 8/group] (Fig. 4B). There was a signiﬁcant treat-
ment  trial-block interaction for freezing during extinction
training (F(7, 98) ¼ 4.82, p < 0.001). Post hoc tests showed signiﬁ-
cantly lower freezing in the AMN082 treated group as compared to
vehicle on trial-blocks 3e8 (Fig. 4B). Freezing was also signiﬁcantly
lower in the AMN082 group than the vehicle group during
extinction retrieval (t14 ¼ 4.24, p < 0.001) (Fig. 4B). The results of
this experiment indicate rescue of impaired S1 extinction learning
and retrieval by AMN082.
3.5. PEPA does not rescue either impaired extinction learning or
retrieval
We next studied the effects PEPA applied before extinction.
During conditioning, freezing increased across trials and did not
differ between groups [ANOVA effect of trial: F(2, 42) ¼ 140.25,
p < 0.001, effect of group: p > 0.05, interaction: p > 0.05, n ¼ 8/
group] (Fig. 5B). Therewas no effect of treatment on freezing during
extinction training and neither group showed a reduction in
freezing across trial-blocks (Fig. 5B). Freezing was also no different
between groups on extinction retrieval (Fig. 5B). These data show
that, unlike VPA and AMN082, PEPA failed to rescue impaired S1
extinction.
3.6. MS-275 does not rescue either impaired extinction learning or
retrieval
In our next experiment, we examined the ability of MS-275,
administered prior to extinction training, to rescue impaired S1
extinction retrieval. Freezing increased across conditioning trials,
and treatment groups did not differ from one another [ANOVA
effect of trial: F(2, 42) ¼ 90.82, p < 0.001, effect of group: p > 0.05,
interaction: p> 0.05, n¼ 7e10/group] (Fig. 6B). There was no effect
of treatment on freezing during extinction training and neither
group showed a reduction in freezing across trial-blocks (Fig. 6B).
Freezing was also no different between groups on extinction
retrieval (Fig. 6B). This experiment shows that, like PEPA, applica-
tion of MS-275 prior to extinction training failed to rescue impaired
S1 extinction.
3.7. After weak conditioning, MS-275 and DCS rescues impaired
extinction retrieval
Our observation that S1 mice can exhibit extinction learning
after weak conditioning, but still have a deﬁcit in extinction
retrieval, led us to test whether two drug treatments shown here
(MCS-275) and previously (DCS) (Hefner et al., 2008) to be inef-
fective in rescuing extinction after normal conditioning would be
effective after weaker conditioning. Freezing increased across
conditioning trials, and treatment groups did not differ from one
another [ANOVA effect of trial: F(2, 50) ¼ 163.80, p < 0.001, effect of
group: p > 0.05, interaction: p > 0.05, n ¼ 9e10/group] (Fig. 7B).
During extinction training, there was a signiﬁcant reduction in
freezing across trials that was similar between groups [ANOVA
effect of trial: F(7, 175) ¼ 88.18, p < 0.001, effect of group: p > 0.05,
interaction: p> 0.05] (Fig. 7B). Micewere treated immediately after
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during extinction retrieval (F(2, 25) ¼ 7.21, p < 0.01). Post hoc tests
showed that freezing was signiﬁcantly lower in the DCS (p < 0.05)
and MS-275 (p < 0.01) treated groups as compared to vehicle
(Fig. 7B). The results of this experiment show that MS-275 and DCS
can rescue impaired extinction retrieval in S1 mice given weak
conditioning.
4. Discussion
The present study revealed a number of novel ﬁndings. Behav-
iourally, we show that using a “weak” fear conditioning paradigm
S1 mice were able to reduce fear during extinction training, but
were unable to consolidate/retrieve this memory during an
extinction retrieval test. This result, in addition to the well
described profound extinction acquisition deﬁcit observed
following “normal” conditioning (Hefner et al., 2008; Camp et al.,
2009; Whittle et al., 2010), reveal that S1 mice, by using graded
conditioning paradigms, can serve as an ideal model to dissociate
whether extinction-promoting interventions act via inducing
extinction acquisition and/or by enhancing extinction consolida-
tion/retrieval. We next assessed a variety of treatments in their
ability to rescue the profound extinction acquisition deﬁcit seen
after normal fear conditioning in S1mice. Herewe show that DBS of
the AcbC during extinction training lowers fear in extinction
retrieval and that pharmacological compounds which enhance
GABAergic signalling in tandemwith HDAC inhibition, or drugs that
activate mGlu7 receptors, rescue extinction acquisition deﬁcits and
lower fear during extinction retrieval in S1 mice. AMPA receptor
potentiation on the other hand was ineffective. Lastly, we revealed
that compounds which enhance NMDA receptor activity or inhibit
HDACs rescue the impaired extinction consolidation/retrieval
deﬁcit in S1 mice.
4.1. Weak fear conditioning in S1 mice permits fear reduction
during extinction training, revealing speciﬁc deﬁciency in extinction
consolidation/retrieval
Present data reveal a novel behavioural ﬁnding that “weak” fear
conditioned S1 mice display impaired extinction consolidation/
retrieval despite successful reduction of fear during extinction
training. No signiﬁcant alterations in either fear learning or fear
expression were observed between “weak” and “normal” fear
conditioned S1 mice demonstrating the selectivity of the extinction
consolidation/retrieval deﬁcit. Importantly, it is unlikely that
sensitisation to the CS contributed to the observed extinction
retrieval deﬁcit as we have previously shown that S1 mice do not
sensitise to the CS (Camp et al., 2009). Collectively, our current data
and that of previously published behavioural ﬁndings showing S1
mice display deﬁcient extinction acquisition following “normal”
fear conditioning (Hefner et al., 2008; Camp et al., 2009; Whittle
et al., 2010), reveal that S1 mice represent a unique model to
determine whether extinction promoting treatments act via
inducing extinction acquisition and/or enhancing extinction
consolidation by using “normal” and “weak” fear conditioning
paradigms.
4.2. DBS of the AcbC during extinction training reduces fear in
a retrieval test session
DBS of the AcbC during extinction training reduced freezing in
the extinction retrieval test indicating a novel treatment to over-
come impaired extinction and thus to reduce learned fear. The AcbC
was chosen based on evidence that stimulation of the AcbC
enhances extinction-like cognitive performance in intractableobsessive-compulsive disorder patients (Lipsman et al., 2007;
Burdick et al., 2009; Goodman et al., 2010; Greenberg et al., 2010;
Grant et al., 2011) and is associatedwith long-term enhancement in
cognitive performance on tests including attention, learning and
memory in remitted depressed patients (Bewernick et al., 2012).
Interestingly, the extinction promoting effect of AcbC stimulation
was independent of any observable reduction of fear during
extinction training. Reasons for this may be inferred from clinical
studies showing that DBS of the AcbC can induce/enhance symp-
toms of fear and panic (palpitations and increased heart rate,
ﬂushing, fearful and panicky feelings) in patients (Shapira et al.,
2006; Okun et al., 2007). Thus, assessment of potential reductions
in freezing behaviour during the extinction session may be overlaid
by enhancing fearful responses by DBS of the AcbC per se.
The exact mechanisms via which DBS of the AcbC promotes
extinction are not fully understood and different hypotheses exist.
DBS has been proposed to cause a functional lesion by suppressing
neural activity at the stimulated brain area, or that DBS elicits
stimulation-induced activation of axons resulting in awide range of
effects on local cells and at a circuit level (McIntyre et al., 2004).
However, existing data indicate that suppression of AcbC activity
may not mediate fear reductions directly since lesions of the AcbC
(Riedel et al., 1997; Levita et al., 2002; Josselyn et al., 2005), or
temporary inactivation (Haralambous and Westbrook, 1999;
Rodriguez-Romaguera et al., 2012) do not disrupt fear responses
regardless of how fear is measured (fear-potentiated startle or
conditioned freezing). In addition, DBS of the AcbC does not evoke
any change in local neurotransmitter release within this brain
region (van Dijk et al., 2011) further negating a direct role of the
AcbC mediating fear reduction. It is possible that DBS of the AcbC
exerts its fear reducing effect at a circuit level to modulate patho-
logical network activity, as our experiment used 130 Hz, 100 mA and
60 ms pulse width, conditions which can inﬂuence ﬁbres of passage
(Nowak and Bullier, 1998a,b) and induce changes in excitability and
plasticity in brain regions critically involved in fear extinction.
Speciﬁcally, DBS of the AcbC selectively increases slow oscillatory
activity (McCracken and Grace, 2009) and supresses pyramidal cell
ﬁring (McCracken and Grace, 2007) in the orbitofrontal cortex, and
increases spontaneous and stimulus-induced coherent activity
between regions in the thalamocortical system, which are impli-
cated in extinction circuitry [e.g. medial prefrontal cortex and
mediodorsal thalamus (Pape and Pare, 2010; Lee et al., 2011)].
Furthermore, increased expression of phosphorylated extra
cellular-regulated kinase (pERK), a marker of cell plasticity (Sweatt,
2004), is observed in brain regions critical for extinction learning
including the medial prefrontal cortex, orbitofrontal cortex, and
a small subregion of the lateral part of the central amygdala
following DBS in the AcbC (Rodriguez-Romaguera et al., 2012),
indicating that many of exactly those areas are targeted by AcbC
DBS that have been shown to be aberrantly activated in extinction-
impaired S1 mice (Whittle et al., 2010). Collectively, our results
reveal for the ﬁrst time that DBS of the AcbC rescued deﬁcient
extinction retrieval in an animal model of impaired extinction,
most likely by positively interfering with the documented cortico-
limbic extinction circuitry failure accompanying the impaired
extinction.
4.3. Enhancing mGlu7 receptor activity during extinction training
reduces fear in S1 mice
We have previously revealed that enhancing the activity of
ionotropic NMDA receptors, via administration of DCS, is ineffective
in inducing extinction acquisition in S1 mice (Hefner et al., 2008).
Here, we investigated whether enhancing the activity of ionotropic
AMPA receptors by administration of PEPA, or metabotropic mGlu7
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tion acquisition deﬁcit in S1. Administration of AMN082, but not
PEPA, prior to an extinction training session induced fear extinction
and also reduced fear during a retrieval test in S1 mice. The lack of
extinction promoting effect of PEPA is in contrast with published
studies in normally behaving mice (Zushida et al., 2007). It is likely
that PEPA, like DCS, facilitates the consolidation of extinction
learning rather than inducing extinction learning per se (Davis et al.,
2006). Evidence supporting this hypothesis is that long-term
potentiation elicited by the AMPA receptor glutamate receptor 1
is necessary for the formation of emotional memories (Humeau
et al., 2007).
The present ﬁnding that AMN082 rescued deﬁcient extinction
acquisition in S1 mice extends recent studies showing that
AMN082, a speciﬁc allosteric modulator of mGlu7 receptors
(Mitsukawa et al., 2005), impairs the acquisition of conditioned fear
as well as facilitates between-session extinction in normally
behaving rodents (Fendt et al., 2008; Siegl et al., 2008). Thus,
AMN082, in addition to dietary zinc-restriction (see ‘Introduction’),
constitute rare examples of treatments which enhance extinction
learning, but not fear learning. Moreover, these results show that
AMN082 can rescue extinction deﬁcits in a psychopathological
animal model, suggesting that AMN082 be used during extinction-
based therapy to induce extinction learning in individuals with
pathological fear.
At present, it is difﬁcult to understand the extinction promoting
effect of AMN082 (O'Connor et al., 2010). mGlu7 receptors, located
entirely pre-synaptically, are widely distributed throughout the
central nervous system (Ohishi et al., 1995). Activation of this
receptor generally inhibits glutamatergic and GABAergic synaptic
transmission (Schoepp, 2001), although facilitation of gluta-
matergic transmission has also been reported in speciﬁc brain
regions (Millan et al., 2002; Li et al., 2008;Martin et al., 2010). Given
the wide-spread distribution of mGlu7 receptors and their location
on both glutamatergic and GABAergic axon terminals, the cumu-
lative excitatory and inhibitory effects of systemic application of
AMN082 is difﬁcult to predict at present as precise knowledge of
the location of the receptor in the microcircuits underlying fear
extinction acquisition is lacking. Further studies on localised effects
of AMN082 are warranted. Furthermore, recent ﬁndings reveal that
a major metabolite of AMN082 inhibits serotonin-, dopamine- and
noradrenaline-transporters (Sukoff Rizzo et al., 2011). As chronic
treatment with the selective serotonin re-uptake inhibitor ﬂuoxe-
tine reduces fear in S1 mice (Camp et al., 2012) and protects against
the return of fear in normally extinguishing mice (Karpova et al.,
2011), we cannot exclude the contribution of enhanced mono-
aminergic neurotransmission in AMN082-induced reduction of
fear.
4.4. Enhancing NMDA receptor activity after successful extinction
learning reduces fear in S1 mice
A meta-analysis of published data shows that DCS is effective in
reducing fear when combined with fear extinction or exposure
therapy (Norberg et al., 2008). Results from normally extinguishing
rodents show that DCS, administered immediately post extinction
training, can lower fear by enhancing extinction memory consoli-
dation (Ledgerwood et al., 2003). Clinically, DCS, combined with
exposure-based therapy, is effective in reducing fear in patients
with so-called simple fears including acrophobia, social anxiety,
obsessive compulsive and panic disorders (Graham et al., 2010).
However, inmost cases beneﬁcial effects of DCSwere only apparent
after a few exposure sessions further suggesting that the primary
mechanism of DCS is to consolidate fear extinction memories.
Along these lines, we have previously published that priorextinction training administration of DCS is ineffective in rescuing
deﬁcient extinction learning in S1 mice (Hefner et al., 2008). Here,
using a novel behavioural ﬁnding that S1 mice display impaired
extinction consolidation/retrieval we tested whether DCS is effec-
tive in lowering fear when administered following successful fear
reduction in extinction learning. Results revealed that DCS rescued
deﬁcient extinction consolidation/retrieval in S1 mice. Thus,
present data and that of Hefner et al. (2008) conclusively demon-
strate that DCS can rescue deﬁcient extinction learning only when
administered during the extinction consolidation phase and that
the efﬁcacy of DCS is gated by the ability of S1 mice to acquire (at
least to some extent) extinction acquisition. These results using
a psychopathological animal model have clinical implications as
they strengthen the suggestion that DCS be used as an add-on drug
to facilitate reductions in fear by exposure therapy in speciﬁc
anxiety disorders (Norberg et al., 2008; Davis, 2011).
4.5. HDAC inhibition rescues deﬁcient extinction consolidation/
retrieval
Recent studies have demonstrated that histone acetylation is
dynamically regulated following successful extinction learning
(Levenson et al., 2004; Fontan-Lozano et al., 2008; Bousiges et al.,
2010; Peleg et al., 2010; Monsey et al., 2011; Stafford et al., 2012),
and furthermore, that pharmacological or genetic silencing of
HDAC enzyme isoforms can enhance fear extinction (Bredy et al.,
2007; Lattal et al., 2007; Bredy and Barad, 2008; Guan et al.,
2009; Monsey et al., 2011). Here, we ﬁrst assessed whether MS-
275, which is, using a chemoproteomic approach a HDAC1- 2-
and 3-isoform inhibitor (Bantscheff et al., 2011), or using puriﬁed
rhHDACs primarily a HDAC1- and 9-isoform inhibitor (Khan et al.,
2008), could rescue deﬁcient extinction consolidation/retrieval in
“weak” fear conditioned S1 mice. We revealed that post extinction
training administration of MS-275, at a dose with demonstrated
HDAC inhibitory properties (Simonini et al., 2006), rescued deﬁ-
cient extinction consolidation/retrieval in S1 mice. It is likely that
combined inhibition of HDAC1-, HADAC2- and HDAC3-isoforms
contributes to the observed rescue of deﬁcient extinction consol-
idation/retrieval in S1 mice. Pharmacological and/or genetic
silencing of HDAC1- or HDAC2-isoforms have been shown to
enhance the consolidation of fear and/or extinction memories
(Guan et al., 2009; Bahari-Javan et al., 2012) and that genetic
silencing of the HDAC3-isoform enhances long term memory in
the object recognition test (McQuown et al., 2011). Notwith-
standing, our data show for the ﬁrst time that preferentially
selective HDAC inhibitors such as MS-275 can rescue profound
extinction consolidation/retrieval deﬁcits in a psychopathological
animal model and thus suggest that such compounds be used as
an add-on drugs to facilitate reductions in fear in exposure-based
therapy.
The extinction consolidation/retrieval-promoting effect of MS-
275 was speciﬁc as results revealed that following “normal” fear
conditioning, in which S1 mice display deﬁcient extinction acqui-
sition, prior extinction training administration of MS-275 did not
induce extinction acquisition or reduce fear during a retrieval test.
This indicates that rescue of deﬁcient extinction acquisition
requires mechanisms beyond HDAC inhibition. As enhancing
GABAergic activity has been shown to signiﬁcantly contribute to
themolecular mechanisms underlying fear extinction [for example,
see (Harris and Westbrook, 1998; Chhatwal et al., 2005; Akirav
et al., 2006; Lin et al., 2009; Dalton et al., 2012)], we tested
whether VPA, a pharmacological compound which enhances
GABAergic signalling (Mimaki et al., 1984; Miller et al., 1988; Ko
et al., 1997; Simonini et al., 2006) in addition to exhibiting robust
HDAC inhibition (Kramer et al., 2003; Khan et al., 2008), can rescue
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dation/retrieval. Indeed, our results revealed that prior extinction
training administration of VPA rescued both deﬁcient extinction
acquisition and deﬁcient extinction consolidation/retrieval in S1
mice. This result in a psychopathological animal model further
extends ﬁndings showing prior extinction training administration
of VPA potentiates reductions in fear extinction in normally extin-
guishing B6 mice (Bredy et al., 2007; Bredy and Barad, 2008) and,
when administered prior to cognitive behavioural therapy, facili-
tates extinction in healthy humans (Kuriyama et al., 2011).
Our current result using a psychopathological animal model
reveals that prior exposure-based extinction training administra-
tion of VPA, acutely applied, can rescue impaired extinction
acquisition and deﬁcient extinction consolidation/retrieval. This
result has clear clinical applications. Speciﬁcally, to date, in
preclinical animal models of impaired fear learning and neuro-
degeneration, cognitive enhancing effects of VPA have been shown
only with chronic prior fear conditioning administration (Li et al.,
2006; Dash et al., 2009; Kilgore et al., 2010). Our present result in
a psychopathological animal model demonstrates the utility of
a single VPA treatment in combination with exposure-based
therapy to rescue impaired extinction acquisition and deﬁcient
extinction consolidation/retrieval. Furthermore, a number of small
clinical studies demonstrate that chronic VPA monotherapy, for
a minimum of eight weeks, reduces fear in social anxiety- (Kinrys
et al., 2003), panic- (Primeau et al., 1990; Keck et al., 1993;
Woodman and Noyes, 1994; Baetz and Bowen,1998) and obsessive-
compulsive- (Cora-Locatelli et al., 1998) disorder patients. Beneﬁ-
cial effects of chronic VPA monotherapy have also been reported in
combat veterans with PTSD (Fesler, 1991; Otte et al., 2004),
however, lacking effects are also reported (Davis et al., 2008;
Hamner et al., 2009). A major drawback to chronic VPA mono-
therapy is that up to 25% of patients within the afore-mentioned
studies are reported to stop medication due to adverse effects
(including nausea, dizziness, fatigue, sedation and gastrointestinal
complaints). Our current data suggests that acute VPA treatment,
combined with exposure-based therapy may be an effective and
novel clinical strategy to reduce fear in anxiety patients with
minimal adverse effects.
5. Conclusions
In summary, we show that S1 mice are a unique psychopatho-
logical animal model as they display deﬁcient extinction acquisi-
tion and deﬁcient extinction retrieval, which can be experimentally
dissociated by choosing different experimental conditioning
setups. Using this mouse model the present data identify novel
therapeutic targets that induce fear reductions when combined
with extinction, resembling exposure-based therapy. Different
pharmacological and non-pharmacological treatments that target
cellular and molecular mechanisms with a documented or putative
role in extinction memory formation within relevant brain areas
and circuitries were chosen. This study reveals that DBS of the AcbC
during exposure-based therapy may be a novel non-
pharmacological treatment strategy to overcome impairments in
reducing learned fear. Furthermore, that pharmacological
enhancement of NMDA receptor activity or inhibition of HDAC1-,
HDAC2- and HDAC3-isoforms, may rescue deﬁcient extinction
retrieval only following successful reductions in fear during
extinction training, which can have important implications for the
use of such agents in human exposure therapy. On the other hand,
enhancing mGlu7 activity or enhancement in GABAergic activity in
tandem with broad inhibition of HDAC isoforms could be a novel
pharmacological treatment strategy to rescue both, impairments in
extinction acquisition and extinction retrieval.Acknowledgements
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